Skip to main content

Table 3 Comparison of demographic and clinical characteristics between skeletal muscle loss and non-skeletal muscle loss groups

From: Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies

Variables SML (No. = 41) Non-SML (No. = 61) P value
Observation period, days, median [range] 632 [153–2902] 785 [184–3278] 0.021
Age, years, median [range] 67 [38–89] 72 [34–88] 0.231
Sex (men/women), n 30/11 40/21 0.515
BMI in men, kg/m2, median [range] 23.5 [17.6–32.7] 23.5 [16.2–33.8] 0.972
BMI in women, kg/m2, median [range] 22.8 [16.0–34.7] 23.2 [17.1–37.5] 0.858
ΔL3 SMI in men, %, median [range] −10.1 [−34.2– −4.7] −0.8 [−4.3–14.2] <  0.001
ΔL3 SMI in women, %, median [range] −8.3 [−25.2– −5.3] 1.4 [−4.5–13.0] <  0.001
Etiology (HBV/HCV/NBNC), n 4/22/15 7/28/26 0.744
ALT, U/L, median [range] 47 (10–243) 37 (9–166) 0.188
Total bilirubin, mg/dL, median [range] 1.1 [0.4–2.4] 0.9 [0.5–3.5] 0.423
Albumin, g/dL, median [range] 3.6 [2.1–4.7] 3.7 [2.0–4.9] 0.026
Platelet count, ×104/μL, median [range] 11.9 [3.4–80.9] 12.1 [2.2–27.1] 0.453
Child-Pugh classification (A/B), n 27/14 41/20 1.000
AFP, ng/mL, median [range] 54 [2.0–633,900] 14 [1.0–40,769] 0.009
TNM stage (I + II/III + IV), n 12/29 21/40 0.668
Maximum tumor diameter, mm, median [range] 50 [10–198] 28 [9–120] 0.009
Number of tumors (solitary/multiple), n 12/29 17/44 1.000
Treatment sessions between CT exams (1/≥ 2, sessions), n 24/17 35/26 1.000
mRECIST assessment (non-PD/PD), n 18/23 35/26 0.227
BCAA supplementation (presence/absence), n 30/11 42/19 0.665
  1. SML skeletal muscle loss, BMI body mass index, ΔL3 SMI rate of change of skeletal muscle mass over 6 months, HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-B non-C, ALT alanine aminotransferase, AFP alpha-fetoprotein, CT computed tomography, mRECIST Modified Response Evaluation Criteria in Solid Tumors, PD progressive disease, BCAA branched-chain amino acid